2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1917

Rheumatoid Arthritis Cells Produce Extracellular Vesicles That Incorporate PD-1 and microRNAs Targeting the PD-1 Pathway in Surrounding Cells

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1551

Rheumatoid Arthritis Is Associated with Low-/Mid-Frequency Hearing Impairment: Data from the Korean National Health and Nutrition Examination Survey

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1236

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1313

Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1418

Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1149

Rheumatology Elective Time in a 4+1 Residency Structure: Evaluating Impact of a Novel Residency Schedule Structure on Rheumatology Resident Education

Education - Poster

9:00AM-11:00AM: Abstract Number: 1886

Right Ventricular Load-Adaptability and Response to Therapy in Scleroderma Versus Idiopathic Pulmonary Arterial Hypertension

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1773

Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1181

Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1798

Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1353

Risk Factors of Pulmonary Mycobacterium Avium-Comlex (MAC) Disease and the Significance of Anti-MAC Antibody in Patients with Rheumatic Diseases

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1496

Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1714

Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1195

Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1660

Role of Immune System Cells and Induction of Netosis-Mediated Cell Death in the Development of Atherosclerosis in Ankylosing Spondylitis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].